Zinc-α2-glycoprotein: Is there association between this new adipokine and body composition in hemodialysis patients?

Renal Failure

Volumn 34, Issue 9, 2012, Pages 1062-1067

  Leal, Viviane O ^a   Lobo, Julie C ^b   Stockler Pinto, Milena B ^b   Farage, Najla E ^c   Velarde, Guillermo C ^a   Fouque, Denis ^d   Leite, M ^b   Mafra, Denise ^a  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Clínica Renalcor   (Brazil)

^d UNIVERSITÉ DE LYON   (France)

Author keywords

Adipokine; Body fat mass; Energy intake; Hemodialysis; Zinc 2 glycoprotein

Indexed keywords

ADIPOCYTOKINE; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ADULT; ANTHROPOMETRY; ARM CIRCUMFERENCE; ARTICLE; BLOOD ANALYSIS; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MALE; MUSCLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84866418046     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.712859     Document Type: Article

References (47)

1. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73: 391-398.
2. Pupim LB, Flakoll PJ, Iklizer TA. Protein homeostasis in chronic hemodialysis patients. Curr Opin Clin Nutr Metab Care. 2004;7: 89-95.
3. Carrero JJ, Chmielewski M, Axelsson J, et al. Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients. Clin Nutr. 2008;27:557-564.
4. Axelsson J, Qureshi R, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease.AmJ Clin Nutr. 2004;80:1222-1229.
5. Ramos LF, Shintani AF, Iklizler TA, Himmerfarb J. Oxidative stress and inflammation are associated with adiposity to moderate to severe CKD. J Am Soc Nephrol. 2008;19:593-599.
6. Gohda T, Gotoh H, Tanimoto M, et al. Relationship between abdominal fat accumulation and insulin resistance in hemodialysis patients. Hypertens Res. 2008;31:83-88.
7. Cordeiro AC, Qureshi AR, Stenvinkel P, et al. Abdominal fat deposition is associated with increased inflammation, protein- energy wasting and worse outcome in patients undergoing hemodialysis. Nephrol Dial Transplant. 2010;25:362-368.
8. Bing C, Bao Y, Jenkins J, et al. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sci USA. 2004;101:2500-2505.
9. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SBGS) adipocytes. FEBS Lett. 2005;579: 41-47.
10. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998;58: 2359-2365.
11. Russel ST, Tisdale MJ. Antidiabetic properties of zinc-alpha2- glycoprotein in ob/ob mice. Endocrinology. 2010;151:948-957.
12. Russell ST, Zimmerman TP, Domin BA, Tisdale MJ. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2- glycoprotein, Biochim. Biophys Acta. 2004;1636:59-68.
13. Gong FY, Zhang SY, Deng JY, et al. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes. 2009;33:1023-1030.
14. Bing C, Russel ST, Beckett EE, et al. Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinomaderived lipid-mobilizing factor. Br J Cancer. 2002;86:612-618.
15. Sanders PM, Tisdale MJ. Effect of zinc-α2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett. 2004;212:71-81.
16. Russel ST, Tisdale MJ. Mechanism of attenuation of skeletal muscle atrophy by zinc-α2-glycoprotein. Endocrinology. 2010; 151:4696-4704.
17. Ceperuello-Mallafré V, Naf S, Escoté X, et al. Circulating and adipose tissue gene expression of zinc-α2-glycoprotein in obesity: Its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat. Endocrine Res. 2009;94: 5062-5069.
18. Selva DM, Lecube A, Hernández C, Baena JA, Fort JM, Simó R. Lower zinc-α2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. Endocrine Res. 2009;94:4499-4507.
19. Yeung DCY, Lam KSL, Wang Y, Tso AWK, Xu A. Serum zinc- α2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. Endocrine Res. 2009;94:2531-2536.
20. Olofsson LE, Olsson B, Lystig T, et al. Preliminary report: Znalpha2- glycoprotein genotype and serum levels are associated with serum lipids. Metab Clin Exp. 2010;59: 1316-1318.
21. Phillipp A, Kralisch S, Bachmann A, et al. Serum levels of the adypokine zinc-α2-glycoprotein are increased in chronic hemodialysis. Metab Clin Exp. 2011;60:669-672.
22. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign: Human Kinetic; 1998.
23. World Health Association/FAO. Expert Consultation on Diet Nutrition and the Prevention of Chronic Diseases. Diet, Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation. Geneva: World Health Consultation; 2003.
24. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr. 1981;34: 2540-2545.
25. National Cholesterol Education Program. Executive summary of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III).J Am Diet Assoc. 2001;285:2486-2497.
26. Durnin JVGA, Womersley J. Body fat assessed from total body density and its estimation from Skinfold thickness: Measurements on 481 men and woman aged from 16 to 72 years. Br J Nutr. 1974;32:77-79.
27. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign: Abridged; 1991.
28. Sargent JA, Gotch FA. Principles and biophysics of dialysis. In: Drukker W, Parsons FM, Maher JA, eds. Replacement of Renal Function by Dialysis. Hague: Martinues Nijhoff; 1985:53.
29. Tabela Brasileira de Composição de Alimentos - TACO. Campinas, Universidade Estadual de Campinas; 2006.
30. Ishimura E, Okuno S, Kim M, et al. Increasing body fat mass in the first year on hemodialysis. J Am Soc Nephrol. 2001;12:1921-1926.
31. Takahashi N, Yuasa S, FukunagaM, et al. Long-term evaluation of nutritional status using dual-energy X-ray absorptiometry in chronic hemodialysis patients. Clin Nephrol. 2003;59:373-378.
32. Spanner E, Suri E, Heidenheim P, Lindsay RM. The impact of quotidian hemodialysis on nutrition. Am J Kidney Dis. 2003;42: S30-S35.
33. Pupim LB, Heimburguer O, Qureshi AR, Ikizler TA, Stenvinkel P. Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int. 2003;42:295-302.
34. Antuna-Punte B, Feve B, Fellahi S, Bastard JD. Adipokines: The missing link between insulin resistance and obesity. Diab Metabol. 2008;34:2-11.
35. Shastri S, Sarnak MJ. Cardiovascular disease and CKD: Core curriculum 2010. Am J Kidney Dis. 2010;56:399-417.
36. Vanholder R, Glorieux G, Van Biesen W. Advantages of new hemodialysis membranes and equipment. Clin Pract. 2010;114:165-172.
37. Stejskal D, Karpísek M, Reutová H, Stejskal P, Kotolová H, Kollár P. Determination of serum zinc-alpha-2- glycoprotein in patients with metabolic syndrome by a new ELISA. Clin Biochem. 2008;41:313-316.
38. Marrades MP, Martínez JA, Moreno-Allaga MJ. ZAG, a lipid mobilizing adipokine, is downregulated in human obesity. J Physiol Biochem. 2008;64:61-66.
39. Dahlman I, Kaaman M, Olsson T, et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab. 2005; 90:5834-5840.
40. Bing C, Mracek T, Gao D, Trayhurn P. Zinc-α2-glycoprotein: An adipokine modulator of body fat mass? Int J Obes. 2010;34: 1559-1565.
41. Fukagawa M, Iwasaki Y, Kazama JJ. Skeletal resistance to parathyroid hormone as a background abnormality in uremia. Nephrology. 2003;8:S50-S52.
42. Chen Y, Biada J, Sood S, Rabkin R. Uremia attenuates growth hormone-stimulated insulin-like growth factor-1 expression, a process worsened by inflammation. Kidney Int. 2010;78:89-95.
43. Carrero JJ, Wistap A, Stenvinkel P, et al. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acid and triglyceride levels. Nephrol Dial Transplant. 2010;25:901-906.
44. Islam-Ali BS, Tisdale MJ. Effect of a tumor-produced lipidmobilizing factor on protein synthesis and degradation. Br J Cancer. 2001;84:1648-1655.
45. Workeneh BT, Mitch WE. Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr. 2010;91: S1128-S1132.
46. Kerr PG, Strauss BJG, Atkins RC. Assessment of the nutritional state of dialysis patients. Blood Purif. 1996;14:121-126.
47. Kamimura MA, Avesani CM, Cenderoglo M, Canziani ME, Draibe S, Cuppari L. Comparison of skinfold thicknesses and bioelectrical impedance analysis with dual-energy X-ray absorptiometry for the assessment of body fat in patients on long-term hemodialysis therapy. Nephrol Dial Transplant. 2003;18:101-105.